Early detection of left ventricular dysfunction in patients with β thalassaemia major by dobutamine stress echocardiography

L Hui, M P Leung, S Y Ha, A K T Chau and Y F Cheung

Heart 2003;89:669-670
doi:10.1136/heart.89.6.669

Updated information and services can be found at:
http://heart.bmjjournals.com/cgi/content/full/89/6/669

These include:

References
2 online articles that cite this article can be accessed at:
http://heart.bmjjournals.com/cgi/content/full/89/6/669#otherarticles

Rapid responses
You can respond to this article at:
http://heart.bmjjournals.com/cgi/eletter-submit/89/6/669

Email alerting service
Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article

Topic collections
Articles on similar topics can be found in the following collections

Other imaging techniques (1496 articles)
Heart Failure (674 articles)

Notes

To order reprints of this article go to:
http://www.bmjjournals.com/cgi/reprintform

To subscribe to Heart go to:
http://www.bmjjournals.com/subscriptions/
Early detection of left ventricular dysfunction in patients with β thalassaemia major by dobutamine stress echocardiography

L Hui, M P Leung, S Y Ha, A K T Chau, Y F Cheung

Myocardial iron deposition, among other factors, contributes to left ventricular (LV) dysfunction in patients with β thalassaemia major. Nonetheless, conventional indices have not been particularly useful for its early detection. Importantly, cardiac function deteriorates rapidly once clinical symptoms develop. Dobutamine stress echocardiography (DSE) is well accepted in the evaluation of myocardial dysfunction caused by coronary artery disease in adults. In children, DSE has been used for early detection of LV dysfunction in long term childhood cancer survivors. In this study, we assessed the usefulness of DSE for early detection of LV dysfunction in thalassaemia patients.

METHODS
Twenty six patients (17 females) with β thalassaemia major with a mean (SD) age of 17.4 (8.3) years (range 4–33 years) were studied. Their body surface area (BSA) was 1.12 (0.20) m². None had congestive heart failure clinically and all were in New York Heart Association (NYHA) functional class I at initial assessment. Monthly blood transfusion was started at a median of 11 months (range 3–96 months), while desferrioxamine was started at a median age of 30 months (range 25–114 months). Post-transfusion haemoglobin was targeted at 14 g/dl (8.7 mmol/l), and echocardiographic studies were performed within one week of transfusion to minimise confounding influence of anaemia. Only one of the patients had undergone splenectomy. Twenty healthy subjects (13 females) aged 10.4 (4.5) years (range 4–15 years), with a BSA of 1.40 (0.23) m², were recruited as controls. The institutional ethics committee approved the study and parents or subjects themselves gave informed consent.

Transthoracic echocardiography was performed using Vingmed System 5 (Horton, Norway) ultrasound machine. Echocardiographic assessments were performed after 15 minutes of rest and after 10 minutes of dobutamine infusion (5 µg/kg/min). Cine-loop data were digitised for offline analysis. Blood pressure was measured using an oscillometric device (Criticat, Dinamap, Tampa, Florida, USA). After the first DSE assessment, a repeated non-stressed echocardiographic assessment was performed in patients at an interval of two years.

Standard parasternal short axis view was used to derive the following: LV end systolic dimension (LVESD), LV end-diastolic dimension (LVEDD) and LV posterior wall thickness at systole (LVPWS). The fractional shortening (FS) and ejection fraction (EF) of the left ventricle were calculated according to standard formulae: FS = [LVEDD - LVESD]/LVEDD; EF = [LVEDD - LVESD]/LVEDD. The aortic ejection time (ET) and RR interval were measured by pulsed Doppler and from surface ECG, respectively. Rate corrected velocity of circumferential fibre shortening (Vcfc) was calculated by Vcfc = RR × FS/ET, while LV systolic meridional wall stress (WS) was calculated by WS = [0.337 × IVESP × LVESD]/LVPWS [1 + LVESP/LVESD]. The peak systolic pressure was used to estimate LV end systolic pressure (LVESP) as this avoided the need for carotid tracing which is technically demanding in children. Average values of indices obtained from three consecutive cardiac cycles were used for analysis. The reference LV myocardial contractility index, a relatively load independent index based on the relation between Vcfc and WS, was derived from controls using linear regression at baseline and under dobutamine stress. Patients with data points lying below the 95% confidence limit were regarded as having impaired myocardial contractility.

Data are expressed as mean (SD). Differences in indices between patients and controls were compared using unpaired Student's t test, while differences between first and second assessments in patients were compared using paired Student's t test. A probability value of p < .05 was considered significant.

RESULTS
There were no significant differences in echocardiographic indices between patients and controls in the first assessment at rest (table 1). Three of the 26 patients, however, had a reduced contractility index. During dobutamine stress, patients had a significantly lower FS, EF, and Vcfc, and a higher WS (table 1). Furthermore, 11 of the 26 patients were found to have a subnormal myocardial contractility index.

Twenty four of the 26 patients underwent a second assessment. One patient, who had impaired LV contractility under dobutamine stress, died of congestive heart failure, while the other declined reassessment. Of the remaining 24 patients, 14 (normal subset) had a normal LV contractility index under dobutamine stress two years earlier, while 10 (abnormal subset) had subnormal LV contractility. For the normal subset, there were no significant differences in echocardiographic indices between the first and second assessments (table 1). All of these patients remained in NYHA functional class I. However, for the abnormal subset, there was a significant reduction in FS, EF, and Vcfc on follow up assessment (table 1). All had a subnormal myocardial contractility index at follow up even in the absence of stress. Furthermore, eight of the 10 patients in the abnormal subset had worsening of the NYHA functional class on follow up, seven in class II and one in class III. Thus a subnormal myocardial contractility index under dobutamine stress has a sensitivity of 80% and a
velocity relation is relatively age independent. Nonetheless, previous studies have shown that the stress–controls was not entirely matched to those of the patients. β be useful for early detection of LV dysfunction in patients with less usually within a 30 second interval. simultaneously with M mode echocardiography, but nonetheless, aortic ET was not assessed diagnosis rather than over diagnosis of patients with impaired myocardial contractility. Thirdly, aortic ET was not assessed secondary to iron deposition, on functional class assessment cannot be completely excluded. While myocardial iron deposition undoubtedly contributes to LV dysfunction, multiple factors including superimposed myocarditis and immunogenetic profile do interact to result in eventual LV failure. The optimal dobutamine dose for assessment of LV reserve in children remains controversial. Nonetheless, frequent side effects has been reported to occur with an infusion rate of ≥ 10 µg/kg/min. As we were assessing myocardial contractile reserve rather than coronary arterial flow limiting lesions, a low dose dobutamine infusion regimen was used. Certain limitations deserve comment. Firstly, the age of the controls was not entirely matched to those of the patients. Nonetheless, previous studies have shown that the stress–velocity relation is relatively age independent. Secondly, the relatively small number of controls might have widened the confidence intervals, which, however, would result in under diagnosis rather than over diagnosis of patients with impaired myocardial contractility. Thirdly, aortic ET was not assessed simultaneously with M mode echocardiography, but nonetheless usually within a 30 second interval.

In conclusion, findings of this study suggest that DSE may be useful for early detection of LV dysfunction in patients with β thalassaemia major.

### DISCUSSION

This study demonstrates that DSE may be useful for early detection of LV dysfunction in thalassaemia patients. Those with impaired myocardial contractility on DSE had a significantly worse functional class and resting LV function at reassessment two years after the first examination. Nonetheless, confounding influence of pulmonary dysfunction, secondary to iron deposition, on functional class assessment cannot be completely excluded. While myocardial iron deposition undoubtedly contributes to LV dysfunction, multiple factors including superimposed myocarditis and immunogenetic profile do interact to result in eventual LV failure. The optimal dobutamine dose for assessment of LV reserve in children remains controversial. Nonetheless, frequent side effects has been reported to occur with an infusion rate of ≥ 10 µg/kg/min. As we were assessing myocardial contractile reserve rather than coronary arterial flow limiting lesions, a low dose dobutamine infusion regimen was used.

Certain limitations deserve comment. Firstly, the age of the controls was not entirely matched to those of the patients. Nonetheless, previous studies have shown that the stress–velocity relation is relatively age independent. Secondly, the relatively small number of controls might have widened the confidence intervals, which, however, would result in under diagnosis rather than over diagnosis of patients with impaired myocardial contractility. Thirdly, aortic ET was not assessed simultaneously with M mode echocardiography, but nonetheless usually within a 30 second interval.

In conclusion, findings of this study suggest that DSE may be useful for early detection of LV dysfunction in patients with β thalassaemia major.

### ACKNOWLEDGEMENT

Funding for this research project was provided by the Children’s Thalassaemia Foundation and the Children’s Heart Foundation.

### REFERENCES